Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph S Bertino

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
The American Journal of Medicine|April 17, 2002
Cost burden of viral respiratory infections: issues for formulary decision makersJoseph S Bertino
Clinical Ophthalmology (Auckland, N.Z.)|October 1, 2009
Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibioticsJoseph S Bertino
Expert Opinion on Pharmacotherapy|September 12, 2009
Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitisJoseph S Bertino, Jin-Zhong Zhang
Journal of Clinical Pharmacology|November 17, 2009
Desirudin dosing and monitoring in moderate renal impairmentAnne N Nafziger, Joseph S Bertino
The Clinical Journal of Pain|January 23, 2009
Utility and application of urine drug testing in chronic pain management with opioidsAnne N Nafziger, Joseph S Bertino
Drugs of Today (Barcelona, Spain : 1998)|November 21, 2009
Besifloxacin ophthalmic suspension for bacterial conjunctivitisAnne N Nafziger, Joseph S Bertino
Pharmacotherapy|September 12, 2002
Evaluation of four once-daily aminoglycoside dosing nomogramsAllison Wood Wallace, Matthew Jones, Joseph S Bertino
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|October 18, 2011
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolonesJohn Segreti, Ronald N Jones, Joseph S Bertino
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolamMaylee Chen, Anne N Nafziger, Joseph S Bertino
The American Journal of Medicine|January 9, 2003
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugsJanyce F Rogers, Anne N Nafziger, Joseph S Bertino
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
The American Journal of Medicine|April 17, 2002
Cost burden of viral respiratory infections: issues for formulary decision makersJoseph S Bertino
Clinical Ophthalmology (Auckland, N.Z.)|October 1, 2009
Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibioticsJoseph S Bertino
Expert Opinion on Pharmacotherapy|September 12, 2009
Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitisJoseph S Bertino, Jin-Zhong Zhang
Journal of Clinical Pharmacology|November 17, 2009
Desirudin dosing and monitoring in moderate renal impairmentAnne N Nafziger, Joseph S Bertino
The Clinical Journal of Pain|January 23, 2009
Utility and application of urine drug testing in chronic pain management with opioidsAnne N Nafziger, Joseph S Bertino
Drugs of Today (Barcelona, Spain : 1998)|November 21, 2009
Besifloxacin ophthalmic suspension for bacterial conjunctivitisAnne N Nafziger, Joseph S Bertino
Pharmacotherapy|September 12, 2002
Evaluation of four once-daily aminoglycoside dosing nomogramsAllison Wood Wallace, Matthew Jones, Joseph S Bertino
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|October 18, 2011
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolonesJohn Segreti, Ronald N Jones, Joseph S Bertino
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolamMaylee Chen, Anne N Nafziger, Joseph S Bertino
The American Journal of Medicine|January 9, 2003
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugsJanyce F Rogers, Anne N Nafziger, Joseph S Bertino
Pageof 6